Pharmaceutical company Hikma Pharmaceuticals said it had received approval from US health authorities for a generic version of Amarin's drug used to treat cardiovascular disease. The company had received approval from the US Food and Drug Administration for its Icosapent Ethyl Capsules, 1 gm, the generic equivalent to Vascepa. In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa patents owned by Amarin. The District Court decision was currently being appealed.
-62.00p (-2.59%)delayed 18:30PM
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.